Because HIF2a functions as an oncogene in VHL-associated and sporadic cases of ccRCC, we treated the vhl−/− mutants with a small-molecule HIF2a inhibitor, Compound 76 (Zimmer et al., 2008; Metelo et al., 2015). This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.